YAP1 is a potential predictive molecular biomarker for response to SMO inhibitor in medulloblastoma cells (2021)
- Authors:
- USP affiliated authors: QUEIROZ, ROSANE GOMES DE PAULA - FMRP ; SCRIDELI, CARLOS ALBERTO - FMRP ; TONE, LUIZ GONZAGA - FMRP ; VALERA, ELVIS TERCI - FMRP ; CRUZEIRO, GUSTAVO ALENCASTRO VEIGA - FMRP ; MAGALHÃES, TACIANI DE ALMEIDA - FMRP ; SOUSA, GRAZIELLA RIBEIRO DE - FMRP ; SILVA, RICARDO BONFIM - FMRP ; BIAGI JÚNIOR, CARLOS ALBERTO OLIVEIRA DE - FMRP ; CHAGAS, PABLO FERREIRA DAS - FMRP
- Unidade: FMRP
- DOI: 10.3390/cancers13246249
- Subjects: MEDULOBLASTOMA; GENÔMICA; NEOPLASIAS; BIOMARCADORES; TERAPIA COMBINADA
- Keywords: SHH medulloblastoma; YAP1; SMO inhibitor
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
CRUZEIRO, Gustavo Alencastro Veiga et al. YAP1 is a potential predictive molecular biomarker for response to SMO inhibitor in medulloblastoma cells. Cancers, v. 13, n. 24, p. 1-11, 2021Tradução . . Disponível em: https://doi.org/10.3390/cancers13246249. Acesso em: 01 abr. 2026. -
APA
Cruzeiro, G. A. V., Magalhães, T. de A., Sousa, G. R. de, Silva, R. B., Biagi Junior, C. A. O. de, Chagas, P. F. das, et al. (2021). YAP1 is a potential predictive molecular biomarker for response to SMO inhibitor in medulloblastoma cells. Cancers, 13( 24), 1-11. doi:10.3390/cancers13246249 -
NLM
Cruzeiro GAV, Magalhães T de A, Sousa GR de, Silva RB, Biagi Junior CAO de, Chagas PF das, Queiroz RG de P, Scrideli CA, Tone LG, Valera ET. YAP1 is a potential predictive molecular biomarker for response to SMO inhibitor in medulloblastoma cells [Internet]. Cancers. 2021 ; 13( 24): 1-11.[citado 2026 abr. 01 ] Available from: https://doi.org/10.3390/cancers13246249 -
Vancouver
Cruzeiro GAV, Magalhães T de A, Sousa GR de, Silva RB, Biagi Junior CAO de, Chagas PF das, Queiroz RG de P, Scrideli CA, Tone LG, Valera ET. YAP1 is a potential predictive molecular biomarker for response to SMO inhibitor in medulloblastoma cells [Internet]. Cancers. 2021 ; 13( 24): 1-11.[citado 2026 abr. 01 ] Available from: https://doi.org/10.3390/cancers13246249 - Frequency of the TP53 p.R337H mutation in a Brazilian cohort of pediatric patients with solid tumors
- CTGF expression is indicative of better survival rates in patients with medulloblastoma
- The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology
- Ultraconserved long non-coding RNA uc.112 is highly expressed in childhood T versus B-cell acute lymphoblastic leukemia
- Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression
- Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup
- Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas
- The interplay between musashi and notch pathways in pediatric medulloblastomas
- Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia
- Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibiblity to acute lymphoblastic leukemia in Brazilian children
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003073627.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
